Great West Life Assurance Co. Can raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 216,080 shares of the pharmaceutical company’s stock after acquiring an additional 2,043 shares during the quarter. Great West Life Assurance Co. Can’s holdings in Vertex Pharmaceuticals were worth $36,750,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. BlackRock Inc. increased its position in Vertex Pharmaceuticals by 2.5% in the 1st quarter. BlackRock Inc. now owns 19,888,045 shares of the pharmaceutical company’s stock valued at $3,241,352,000 after acquiring an additional 478,972 shares in the last quarter. Wells Fargo & Company MN increased its position in Vertex Pharmaceuticals by 4.1% in the 2nd quarter. Wells Fargo & Company MN now owns 2,087,508 shares of the pharmaceutical company’s stock valued at $354,794,000 after acquiring an additional 82,811 shares in the last quarter. Fred Alger Management Inc. increased its position in Vertex Pharmaceuticals by 10.8% in the 2nd quarter. Fred Alger Management Inc. now owns 1,960,493 shares of the pharmaceutical company’s stock valued at $333,205,000 after acquiring an additional 191,072 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in Vertex Pharmaceuticals by 9.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,663,552 shares of the pharmaceutical company’s stock valued at $282,738,000 after acquiring an additional 143,730 shares in the last quarter. Finally, Standard Life Aberdeen plc increased its position in Vertex Pharmaceuticals by 238.9% in the 2nd quarter. Standard Life Aberdeen plc now owns 1,144,913 shares of the pharmaceutical company’s stock valued at $194,646,000 after acquiring an additional 807,086 shares in the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

In related news, SVP Paul M. Silva sold 2,957 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, June 29th. The shares were sold at an average price of $166.52, for a total transaction of $492,399.64. Following the transaction, the senior vice president now owns 16,946 shares of the company’s stock, valued at approximately $2,821,847.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey M. Leiden sold 140,211 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, June 22nd. The stock was sold at an average price of $160.00, for a total transaction of $22,433,760.00. Following the transaction, the chief executive officer now directly owns 297,260 shares in the company, valued at approximately $47,561,600. The disclosure for this sale can be found here. Insiders have sold a total of 206,665 shares of company stock worth $33,749,025 in the last three months. 1.80% of the stock is owned by insiders.

Several equities research analysts have recently commented on VRTX shares. BidaskClub upgraded shares of Vertex Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 16th. BMO Capital Markets lifted their price target on shares of Vertex Pharmaceuticals to $204.00 and gave the stock an “outperform” rating in a research report on Thursday, July 26th. Jefferies Financial Group lifted their price target on shares of Vertex Pharmaceuticals to $210.00 and gave the stock a “buy” rating in a research report on Monday, July 16th. UBS Group lifted their price target on shares of Vertex Pharmaceuticals from $183.00 to $188.00 and gave the stock a “neutral” rating in a research report on Thursday, July 26th. Finally, Oppenheimer lifted their price target on shares of Vertex Pharmaceuticals from $180.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, July 26th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-three have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $195.79.

Vertex Pharmaceuticals stock opened at $186.03 on Friday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $136.50 and a fifty-two week high of $186.44. The company has a market cap of $45.83 billion, a P/E ratio of 232.54, a PEG ratio of 1.83 and a beta of 1.48. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.55 and a current ratio of 3.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Wednesday, July 25th. The pharmaceutical company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.54. Vertex Pharmaceuticals had a net margin of 15.84% and a return on equity of 19.86%. The business had revenue of $752.20 million for the quarter, compared to analyst estimates of $680.86 million. During the same quarter last year, the firm earned $0.39 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 38.2% compared to the same quarter last year. analysts expect that Vertex Pharmaceuticals Incorporated will post 2.48 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

Recommended Story: New Google Finance Tool and Screening Stocks

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.